Unknown

Dataset Information

0

Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial.


ABSTRACT: Denosumab, a RANKL inhibitor, reduced the risk of vertebral, hip, and nonvertebral fractures in the Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) trial of postmenopausal women with osteoporosis compared with placebo. Previous bone histomorphometric analysis in FREEDOM showed decreased bone resorption and turnover in cancellous bone after 2 and 3 years. The purpose of the present study was to evaluate the effects of denosumab compared with placebo in the cortical compartment from transiliac bone biopsies obtained during FREEDOM. A total of 112 specimens were evaluable for cortical histomorphometry, including 67 obtained at month 24 (37 placebo, 30 denosumab) and 45 at month 36 (25 placebo, 20 denosumab). Eroded surface, osteoclast surface, erosion depth, and wall thickness were measured on the endocortical surface. Cortical thickness and cortical porosity were also measured. Dynamic parameters of bone formation were assessed for endocortical, periosteal, and intracortical envelopes. Endocortical osteoclast surface, eroded surface, and mean and maximum erosion depth were significantly lower in the denosumab group versus placebo at months 24 and 36 (p?

SUBMITTER: Chavassieux P 

PROVIDER: S-EPMC6850394 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial.

Chavassieux Pascale P   Portero-Muzy Nathalie N   Roux Jean Paul JP   Horlait Stéphane S   Dempster David W DW   Wang Andrea A   Wagman Rachel B RB   Chapurlat Roland R  

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20190102 4


Denosumab, a RANKL inhibitor, reduced the risk of vertebral, hip, and nonvertebral fractures in the Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) trial of postmenopausal women with osteoporosis compared with placebo. Previous bone histomorphometric analysis in FREEDOM showed decreased bone resorption and turnover in cancellous bone after 2 and 3 years. The purpose of the present study was to evaluate the effects of denosumab compared with placebo in the cort  ...[more]

Similar Datasets

| S-EPMC6037073 | biostudies-literature
| S-EPMC6719332 | biostudies-literature
| S-EPMC3288521 | biostudies-literature
| S-EPMC7745880 | biostudies-literature
| S-EPMC3222788 | biostudies-literature
| S-EPMC4445722 | biostudies-literature
| S-EPMC6020114 | biostudies-literature
| S-EPMC6259258 | biostudies-literature
| S-EPMC6556726 | biostudies-literature
| S-EPMC6909937 | biostudies-literature